MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
22.11
+0.41
+1.89%
After Hours: 22.55 +0.44 +1.99% 19:40 12/04 EST
OPEN
21.52
PREV CLOSE
21.70
HIGH
22.13
LOW
21.43
VOLUME
916.90K
TURNOVER
--
52 WEEK HIGH
22.83
52 WEEK LOW
6.42
MARKET CAP
1.18B
P/E (TTM)
-11.7631
1D
5D
1M
3M
1Y
5Y
1D
Tyra Biosciences initiated as Early-Stage Biotech at Goldman Sachs
TipRanks · 19h ago
Tyra Biosciences (TYRA): Assessing Valuation After New Leadership Hires to Drive Dabogratinib Pipeline Forward
Simply Wall St · 1d ago
Should Tyra Biosciences’ (TYRA) Executive Hires Shift the Regulatory Outlook for Its Pipeline?
Simply Wall St · 2d ago
Tyra Biosciences Inc. Files Initial Statement of Beneficial Ownership for COO Bhavesh Ashar
Reuters · 3d ago
Tyra Bioscience Appoints Bhavesh Ashar as COO
TipRanks · 3d ago
Tyra Biosciences Appoints Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer
Reuters · 3d ago
BRIEF-Tyra Biosciences Strengthens Leadership Team With Appointments Of Bhavesh Ashar As Chief Operating Officer And Heather Faulds As Chief Regulatory Officer
Reuters · 3d ago
Press Release: Tyra Biosciences Strengthens -2-
Dow Jones · 3d ago
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.